Screener / SEC EDGAR /CIK 0001159036 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Halozyme Therapeutics, Inc. HALO

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What HALO's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 5, 2026, HALO reported $2.01 per share under GAAP and $2.39 on its own adjusted basis: the adjusted number is +19% above GAAP.

GAAP EPS $0.65, release Feb 20, 2024: EPS of $3.55-3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.82 1 Ful Adjusted EPS $2.77, release Feb 20, 2024: GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.77 1 Announcing New $750 million Share Repurchase Program SAN DIEGO, February 20, 2024 -- Halozyme Therapeutics, Inc. +326% 2024-02 GAAP EPS $0.60, release May 7, 2024: Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Roy Adjusted EPS $0.79, release May 7, 2024: GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to +32% 2024-05 GAAP EPS $0.72, release Aug 6, 2024: Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus ® SC in Europe and the UK and VYVGART ® Hytrulo for CIDP in the U.S. Adjusted EPS $0.91, release Aug 6, 2024: GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus ® SC in Europe and the UK and VYVGART ® Hytrulo for CIDP in the U.S. +26% 2024-08 GAAP EPS $1.05, release Oct 31, 2024: million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% Adjusted EPS $4.00, release Oct 31, 2024: Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-5 +281% 2024-10 GAAP EPS $3.22, release Jan 8, 2025: million Royalty Revenue $550 to $565 million Net Income $419 to $443 million Adjusted EBITDA $595 to $625 million GAAP Diluted EPS $3.22 to $3.40 Non-GAAP Diluted EPS $4.00 to Adjusted EPS $4.00, release Jan 8, 2025: to $565 million Net Income $419 to $443 million Adjusted EBITDA $595 to $625 million GAAP Diluted EPS $3.22 to $3.40 Non-GAAP Diluted EPS $4.00 to $4.20 Footnotes: 1 Growth rates calc +24% 2025-01 GAAP EPS $1.06, release Feb 18, 2025: GAAP diluted earnings per share was $1.06, compared to $0.65 in the fourth quarter of 2023. Adjusted EPS $1.26, release Feb 18, 2025: Non-GAAP diluted earnings per share was $1.26, compared to $0.82 in the fourth quarter of 2023. +19% 2025-02 GAAP EPS $0.93, release May 6, 2025: Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93 Adjusted EPS $5.30, release May 6, 2025: YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% +470% 2025-05 GAAP EPS $1.33, release Aug 5, 2025: Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33 Adjusted EPS $6.00, release Aug 5, 2025: YOY Growth of 26% - 33%, Adjusted EBITDA to $865 - $915 million, Representing YOY Growth of 37% - 45% and Non-GAAP Diluted EPS to $6.00 - $6.40, Representing YOY Growth of 42% +351% 2025-08 GAAP EPS $1.43, release Nov 3, 2025: Adjusted EBITDA Increased 35% YOY to $248 million; GAAP Diluted EPS Increased 36% YOY to $1.43 Adjusted EPS $6.10, release Nov 3, 2025: YOY Growth of 28% - 35%, Adjusted EBITDA to $885 - $935 million, Representing YOY Growth of 40% - 48% and Non-GAAP Diluted EPS to $6.10 - $6.50, Representing YOY Growth of 44% +327% 2025-11 GAAP EPS $1.22, release May 11, 2026: GAAP diluted earnings per share was $1.22, compared to $0.93 in the first quarter of 2025. Adjusted EPS $1.60, release May 11, 2026: Non-GAAP diluted earnings per share was $1.60, compared to $1.11 in the first quarter of 2025. +31% 2026-05 GAAP EPS $1.90, release Aug 6, 2026: GAAP diluted earnings per share was $1.90, compared to $1.33 in the second quarter of 2025. Adjusted EPS $2.28, release Aug 6, 2026: Non-GAAP diluted earnings per share was $2.28, compared to $1.54 in the second quarter of 2025. +20% 2026-08 GAAP EPS $2.01, release Nov 5, 2026: GAAP diluted earnings per share was $2.01, compared to $1.43 in the third quarter of 2025. Adjusted EPS $2.39, release Nov 5, 2026: Non-GAAP diluted earnings per share was $2.39, compared to $1.72 in the third quarter of 2025. +19% 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
GAAP diluted earnings per share was $2.01, compared to $1.43 in the third quarter of 2025. release
Non-GAAP diluted earnings per share was $2.39, compared to $1.72 in the third quarter of 2025. release

What the company says its adjusted numbers leave out:

The Company calculates Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and share-based compensation acceleration expenses, intellectual property litigation costs, inducement expenses related to convertible notes, and certain adjustments to income tax expense. release Nov 5, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND

Open on SEC

-- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the third quarter ended September 30, 2026, and provided an update on its recent corporate activities.

“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels,” said Dr. Helen Torley, President and Chief Executive Officer. “In and post the quarter, we have achieved multiple milestones that expand our opportunity and diversify our revenue. During the quarter, we expanded our agreements with argenx and Incyte to include additional targets to be evaluated with ENHANZE. In October, we also signed an expanded agreement with Johnson & Johnson for one additional target. Three ENHANZE programs, one each with Pfizer, Incyte and argenx advanced into Phase 1 clinical development, bringing our total products in development to twelve.”

Dr. Torley continued, “In October, we also achieved an important victory in protecting our intellectual property. The Dutch specialized patent court found that Merck is infringing one of our MDASE patents and granted an injunction prohibiting the launch of Keytruda Qlex in multiple European markets. Our commitment to protecting the value of our innovations, growing royalties, continued partner expansion and growing pipeline demonstrates the power of Halozyme’s compounding platform engine and positions us to deliver durable revenue well into the next decade.”

“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026,” said Darren Snellgrove, Executive Vice President and Chief Financial Officer. “We also further strengthened our financial position with the successful completion of our $1.5 billion convertible notes, which enhances our flexibility to execute our disciplined capital allocation strategy. We completed $400 million in share repurchases this year while continuing to invest in our highest-return organic opportunities and maintaining a clear path to retire our remaining 2027 and

2028 notes at maturity. With our strong cash generation, we remain focused on capital deployment to maximize long-term value creation.”

• In October 2026, the Company announced the specialized Dutch patent court of the Hague found Merck Sharp & Dohme B.V. (“MSD BV”), the central European Market Authorization holder for Merck & Co., Inc., to be infringing one of Halozyme’s MDASE™ patents and ordered MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda Qlex in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD BV to facilitate infringement by its affiliates in those countries, including by allowing the use of its European Marketing Authorization. The court also rejected MSD BV’s arguments that the patent is invalid.

• During the third quarter of 2026, Halozyme repurchased approximately 0.8 million shares for $67.2 million at an average price of $79.47 per share under the May 2026 share repurchase program, resulting in $400 million of share repurchases in 2026.

• In October 2026, Takeda announced a Biologics License Application was filed with the Food and Drug Administration (“FDA”) for TAK-881 for the treatment of Primary Immunodeficiency Disease.

• In October 2026, Janssen expanded its collaboration and licensing agreement with us for an additional oncology target to be developed with ENHANZE ® .

• In October 2026, Roche announced the FDA has approved TECENTRIQ ® (atezolizumab) and TECENTRIQ HYBREZA ® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (“dMMR”) colon cancer, a type of tumour characterized by high mutation rates. This approval marks the twelfth indication for TECENTRIQ in the U.S.

• In the third quarter of 2026, argenx submitted a supplemental Biologics License Application for VYVGART ® in ocular myasthenia gravis to the FDA.

• In September 2026, argenx expanded its collaboration and licensing agreement by nominating two additional targets which provides exclusive access to ENHANZE ® for a total of eight targets.

• In September 2026, Pfizer initiated a Phase 1 study to evaluate the pharmacokinetics of a single SC dose of tilrekimig with ENHANZE ® in healthy adults. Tilrekimig is a trispecific monoclonal antibody being developed for the treatment of atopic dermatitis, asthma, and chronic obstructive pulmonary disease.

• In September 2026, Halozyme and Incyte expanded their collaboration to evaluate the SC formulation of axatilimab, a monoclonal antibody targeting colony-simulating factor-1 receptor, with ENHANZE ® . Under the terms of the new target agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE ® .

• In August 2026, GSK disclosed plans to initiate a Phase 1b study to evaluate the pharmacokinetics and safety of a SC belantamab formulation with ENHANZE ® versus IV belantamab in patients with multiple myeloma while treated with standard of care.

• The SC formulation of INCA033989, a first-in-class mutant calreticulin- targeted monoclonal antibody utilizing ENHANZE ® drug delivery technology is being evaluated in an ongoing Phase 1 study.

• In July 2026, Halozyme and Incyte entered into a global collaboration and license agreement to evaluate additional SC formulations of INCA033989, a first- in-class mutant calreticulin-targeted monoclonal antibody, in patients with mutant calreticulin expressing myeloproliferative neoplasms, utilizing Halozyme’s proprietary ENHANZE ® drug delivery technology. Under the collaboration, Incyte also has the option to nominate up to two additional targets for use with ENHANZE ® . Under the terms of the agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE ® .

• In July 2026, Janssen announced the FDA granted priority review of the supplemental Biologics License Application filing for SC amivantamab and hyaluronidase-lpuj in adults with head and neck squamous cell carcinoma.

• In the third quarter of 2026, the ongoing ARGX-119 adimanebart program was expanded to include a Phase 1 SC bioavailability study with ENHANZE ® . Third Quarter 2026 Financial Highlights: • Total revenue was $493.0 million, compared to $354.3 million in the third quarter of 2025. The 39% year-over-year increase was primarily driven by royalty revenue growth and an increase in product sales. Revenue included $341.0 million in royalties, an increase of 44% compared to $236.0 million in the third quarter of 2025, primarily driven by continued sales uptake of ENHANZE ® partner products that have launched since 2020, predominantly by VYVGART ® Hytrulo by argenx, DARZALEX ® SC by Janssen, and Phesgo by Roche in all geographies and contributions from other recently launched products.

• Cost of sales was $82.5 million, compared to $55.2 million in the third quarter of 2025. The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales.

• Amortization of intangibles expense was $29.5 million, compared to $17.8 million in the third quarter of 2025. The increase in amortization of intangibles expense was due to the acquisition of Elektrofi, Inc. (“Elektrofi”) in November 2025.

• Research and development expense was $27.8 million, compared to $17.3 million in the third quarter of 2025. The increase was primarily due to the acquisition of Elektrofi and Surf Bio, Inc. in the fourth quarter of 2025.

• Selling, general and administrative expense was $58.2 million, compared to $46.1 million in the third quarter of 2025. The increase was primarily due to an increase in consulting and professional service fees, including litigation costs incurred in connection with a patent infringement litigation case, the acquisition of Elektrofi, and an increase in compensation expense.

• Operating income was $295.0 million, compared to $217.9 million in the third quarter of 2025.

• Net income was $247.0 million, compared to $175.2 million in the third quarter of 2025.

• EBITDA was $328.7 million, compared to $238.3 million in the third quarter of 2025. Adjusted EBITDA was $336.2 million, compared to $248.2 million in the third quarter of 2025. 1

• GAAP diluted earnings per share was $2.01, compared to $1.43 in the third quarter of 2025. Non-GAAP diluted earnings per share was $2.39, compared to $1.72 in the third quarter of 2025. 1

• Cash, cash equivalents, restricted cash and marketable securities were $1.08 billion on September 30, 2026, compared to $145.4 million on December 31, 2025. The increase was primarily driven by the issuance of convertible notes and cash generated from operations.

The Company is raising its 2026 financial guidance ranges, which were last updated on August 6, 2026. For the full year 2026, the Company expects: • Total revenue of $1.860 billion to $1.925 billion, representing growth of 33% to 38% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API.

• Revenue from royalties of $1.235 billion to $1.255 billion, representing growth of 42% to 45% over 2025.

• Adjusted EBITDA of $1.240 billion to $1.290 billion, representing growth of 89% to 96% over 2025, including new Hypercon™ and Aerocon™ investments of approximately $60 million.

• Non-GAAP diluted earnings per share of $8.75 to $9.05, representing growth of 111% to 118% over 2025. The Company’s earnings per share guidance includes new Hypercon™ and Aerocon™ investments of approximately $60 million and does not consider the impact of potential future share repurchases.

Previous Guidance Range New Guidance Range Total Revenue $1.835 to $1.910 billion $1.860 to $1.925 billion Royalty Revenue $1.220 to $1.245 billion $1.235 to $1.255 billion Adjusted EBITDA1 $1.225 to $1.280 billion $1.240 to $1.290 billion Non-GAAP Diluted EPS1 $8.65 to $9.00 $8.75 to $9.05

1 EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. Reconciliations between GAAP reported and Non- GAAP financial information for actual results are provided at the end of this earnings release.

Halozyme will host its Quarterly Update Conference Call for the third quarter ended September 30, 2026 today, Thursday, November 5, 2026, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: https://events.q4inc.com/analyst/811361061?pwd=qhqAVQ9L . The call will also be webcast live through the “Investors” section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com.

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden and improving convenience. ENHANZE ® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol- Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio’s hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is microparticle technology with the potential to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Aerocon™ polymer-based hyperconcentration technology may further broaden the range of biologics that can be delivered

subcutaneously. Together, we believe Hypercon™ and Aerocon™ technology complement ENHANZE ® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex ® and XYOSTED ® , partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying tables contain certain Non-GAAP financial measures. The Company reports earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted EBITDA, Non-GAAP diluted earnings per share, Non-GAAP diluted shares, and guidance with respect to those measures, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and share-based compensation acceleration expenses and intellectual property litigation costs. The Company calculates Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and share-based compensation acceleration expenses, intellectual property litigation costs, inducement expenses related to convertible notes, and certain adjustments to income tax expense. The Company calculates Non-GAAP diluted shares excluding the dilutive impact of convertible notes which is used in calculating Non-GAAP diluted earnings per share. Reconciliations between GAAP and Non-GAAP financial measures are included at the end of this press release. The Company does not provide reconciliations for forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in share- based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides Non-GAAP financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the Non-GAAP measures.

The Company evaluates other items of income and expense on an individual basis for potential inclusion in the calculation of Non-GAAP financial measures and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company’s ongoing business operations and (iii) whether or not the Company expects it to occur as part of the Company’s normal business on a regular basis. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similarly titled measures presented by other companies. These Non- GAAP financial measures are not meant to be considered in isolation and should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP, and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures, and the Company may in

the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures.

The Company considers these Non-GAAP financial measures to be important because they provide useful measures of the operating performance of the Company, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The Non-GAAP measures also allow investors and analysts to make additional comparisons of the operating activities of the Company’s core business over time and with respect to other companies, as well as assessing trends and future expectations. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs.

In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company’s financial performance (including the Company’s expected financial outlook for 2026) and expectations for future growth, profitability, revenue durability and diversity, total revenue, royalty revenue, royalty revenue duration, EBITDA, Adjusted EBITDA, and non-GAAP diluted earnings-per-share, and shareholder value and retirement of outstanding debt. These forward-looking statements also include statements regarding the injunction issued by the specialized Dutch patent court of the Hague and other findings of the court mentioned in this press release, the Company’s potential receipt of upfront payments and payments associated with achievement of certain development, regulatory and sales-based milestones, and royalties on sales of commercialized products from our collaboration agreements. Forward-looking statements regarding the Company’s ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery including its potential application with antibody drug conjugates. Forward-looking statements regarding the Company’s Hypercon™ and Aerocon™ technologies include the possible benefits and attributes of these technologies, including the potential to reduce injection volume for the same dosage of drugs and biologics and possibly enabling administration in at‑home and healthcare‑provider settings and statements concerning certain other potential benefits of these technologies including facilitating administration of injectable medications through subcutaneous delivery by enabling creation and delivery of highly concentrated biologics and potentially lowering the treatment burden, easing treatment access and improving the treatment experience for patients. Forward-looking statements regarding the Company’s business may include potential growth and receipt of royalty and milestone payments driven by our partners’ development and commercialization efforts, potential new clinical trial study starts and advancement of partnered development programs, regulatory submissions and product launches, the size and growth prospects of our partners’ drug franchises, potential new or expanded collaborations and collaborative targets, and potential approvals of new partnered or proprietary products, and the potential timing of these events. These forward-looking statements are typically, but not always, identified through use of the words “expect,” “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “preliminary,” “possible,” “should,” “continue,” and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including uncertainties concerning future matters such as unexpected changes in market conditions, changes in domestic and foreign business, changes in the competitive environment in which the Company operates, judicial decisions related to the injunction and other judicial findings mentioned in this press release, unexpected early expiration or termination of the patent terms for the Company’s drug delivery technologies, unexpected levels of revenues, expenditures and costs, unexpected results or delays in the growth of the Company’s business, or in the development, regulatory review or commercialization of the Company’s partnered or proprietary products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contact:

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets Cash and cash equivalents $ 1,029,988 $ 133,820 Marketable securities, 44,399 9,000 available-for-sale Accounts receivable, net and contract 525,592 441,273 assets Inventories 132,613 176,475 Prepaid expenses and other current 114,138 64,639 assets Total current assets 1,846,730 825,207 Property and equipment, net 82,286 82,137 Prepaid expenses and other assets 68,806 53,551 Goodwill 581,732 580,360 Intangible assets, net 892,931 981,467 Restricted cash 861 2,601 Total assets $ 3,473,346 $ 2,525,323 LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities Accounts payable $ 33,546 $ 20,899 Accrued expenses 136,930 156,193 Current portion of long-term debt, 305,612 — net Total current liabilities 476,088 177,092 Long-term debt, net 2,944,691 2,142,630 Other long-term liabilities 101,466 113,863 Deferred tax liabilities, net 6,340 42,924 Total liabilities 3,528,585 2,476,509 Stockholders’ (deficit) equity Common stock 114 118 Additional paid-in capital — 12,002 Accumulated other comprehensive loss 2,781 -18,092 (Accumulated Deficit) Retained -58,134 54,786 earnings Total stockholders’ (deficit) equity -55,239 48,814 Total liabilities and stockholders’ $ 3,473,346 $ 2,525,323 (deficit) equity

(1) Amount represents incremental costs including legal and advisory fees incurred in association with the acquisition of Elektrofi.

(2) Adjustment relates to litigation costs incurred by Halozyme in connection with Halozyme’s patent infringement litigation against Merck Sharp & Dohme LLC (“Merck”). These charges are excluded because the Company does not believe they are reflective of the Company’s ongoing business and operating results.

Three Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── GAAP Net Income $ 247,049 $ 175,225 Adjustments Inducement expense related to 465 — convertible notes Share-based 16,802 12,160 compensation Amortization of 2,220 1,858 debt discount Amortization of intangible 29,512 17,762 assets Transaction costs for — 3,871 business combinations(1) Intellectual property 7,452 6,038 litigation costs(2) Income tax effect of above -19,699 -10,120 adjustments(3) Non-GAAP Net $ 283,801 $ 206,794 Income GAAP Diluted $ 2.01 $ 1.43 EPS Adjustments Inducement expense related to 0.01 — convertible notes Share-based 0.15 0.10 compensation Amortization of 0.02 0.02 debt discount Amortization of intangible 0.25 0.15 assets Transaction costs for — 0.03 business combinations(1) Intellectual property 0.07 0.05 litigation costs(2) Income tax effect of above -0.17 -0.08 adjustments(3) Non-GAAP $ 2.39 $ 1.72 Diluted EPS GAAP Diluted 122,611 122,331 Shares Adjustments Adjustment for dilutive impact of -3,728 -2,014 convertible notes(4) Non-GAAP 118,883 120,317 Diluted Shares

(1) Amount represents incremental costs including legal and advisory fees incurred in association with the acquisition of Elektrofi.

(2) Adjustment relates to litigation costs incurred by Halozyme in connection with Halozyme’s patent infringement litigation against Merck. These charges are excluded because the Company does not believe they are reflective of the Company’s ongoing business and operating results.

(3) Adjustments relate to taxes for the reconciling items, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items.

(4) Adjustment made for the dilutive effect of our convertible notes due 2028, 2031 and 2032 when the effect is not the same on a GAAP and Non-GAAP basis for the reporting period.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND                 
                                                                                
                                                                                
                    RAISES FULL YEAR 2026 FINANCIAL GUIDANCE                    
                                                                                
                Total Revenue Increased 39% YOY to $493 million                 
                                                                                
               Royalty Revenue Increased 44% YOY to $341 million                
                                                                                
                    Raising 2026 Financial Guidance Ranges:                     
                                                                                
       Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38%        
                                                                                
      Royalty Revenue of $1.235 - $1.255 billion, YOY Growth of 42% - 45%       
                                                                                
     Adjusted EBITDA of $1.240 - $1.290 billion, YOY Growth of 89% - 96% 1      
                                                                                
       Non-GAAP Diluted EPS of $8.75 - $9.05, YOY Growth of 111% - 118% 1       
                                                                                
    Expanded ENHANZE ® Collaboration Agreements with Three Current Partners     
                                                                                
      Three ENHANZE ® Programs Advanced into Phase 1 Clinical Development       
                                                                                
  SAN DIEGO, November 5, 2026                                                   
                                                                                
-- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”)
today reported its financial and operating results for the third quarter ended
September 30, 2026, and provided an update on its recent corporate activities.

“Halozyme delivered another exceptional quarter, with total revenue increasing
39% and royalty revenue growing 44% year-over-year to record levels,” said Dr.
Helen Torley, President and Chief Executive Officer. “In and post the quarter,
we have achieved multiple milestones that expand our opportunity and diversify
our revenue. During the quarter, we expanded our agreements with argenx and
Incyte to include additional targets to be evaluated with ENHANZE. In October,
we also signed an expanded agreement with Johnson & Johnson for one additional
target. Three ENHANZE programs, one each with Pfizer, Incyte and argenx advanced
into Phase 1 clinical development, bringing our total products in development to
twelve.”

Dr. Torley continued, “In October, we also achieved an important victory in
protecting our intellectual property. The Dutch specialized patent court found
that Merck is infringing one of our MDASE patents and granted an injunction
prohibiting the launch of Keytruda Qlex in multiple European markets. Our
commitment to protecting the value of our innovations, growing royalties,
continued partner expansion and growing pipeline demonstrates the power of
Halozyme’s compounding platform engine and positions us to deliver durable
revenue well into the next decade.”

“Based on our strong financial performance this quarter, we are pleased to be
able to raise our guidance for the full year 2026,” said Darren Snellgrove,
Executive Vice President and Chief Financial Officer. “We also further
strengthened our financial position with the successful completion of our $1.5
billion convertible notes, which enhances our flexibility to execute our
disciplined capital allocation strategy. We completed $400 million in share
repurchases this year while continuing to invest in our highest-return organic
opportunities and maintaining a clear path to retire our remaining 2027 and

2028 notes at maturity. With our strong cash generation, we remain focused on
capital deployment to maximize long-term value creation.”

Recent and Third Quarter Corporate Highlights:

• In October 2026, the Company announced the specialized Dutch patent court of
the Hague found Merck Sharp & Dohme B.V. (“MSD BV”), the central European Market
Authorization holder for Merck & Co., Inc., to be infringing one of Halozyme’s
MDASE™ patents and ordered MSD BV to refrain from manufacturing, having
manufactured, offering, placing on the market and using, or importing or
stocking for these purposes, Keytruda Qlex in Belgium, Denmark, France, Ireland,
Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD
BV to facilitate infringement by its affiliates in those countries, including by
allowing the use of its European Marketing Authorization. The court also
rejected MSD BV’s arguments that the patent is invalid.

• During the third quarter of 2026, Halozyme repurchased approximately 0.8
million shares for $67.2 million at an average price of $79.47 per share under
the May 2026 share repurchase program, resulting in $400 million of share
repurchases in 2026.

Recent Partner Highlights:

• In October 2026, Takeda announced a Biologics License Application was filed
with the Food and Drug Administration (“FDA”) for TAK-881 for the treatment of
Primary Immunodeficiency Disease.

• In October 2026, Janssen expanded its collaboration and licensing agreement
with us for an additional oncology target to be developed with ENHANZE ® .

• In October 2026, Roche announced the FDA has approved TECENTRIQ ®
(atezolizumab) and TECENTRIQ HYBREZA ® (atezolizumab and hyaluronidase-tqjs) in
combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment
of stage III deficient DNA mismatch repair (“dMMR”) colon cancer, a type of
tumour characterized by high mutation rates. This approval marks the twelfth
indication for TECENTRIQ in the U.S.

Third Quarter Partner Highlights:

• In the third quarter of 2026, argenx submitted a supplemental Biologics
License Application for VYVGART ® in ocular myasthenia gravis to the FDA.

• In September 2026, argenx expanded its collaboration and licensing agreement
by nominating two additional targets which provides exclusive access to ENHANZE
® for a total of eight targets.

• In September 2026, Pfizer initiated a Phase 1 study to evaluate the
pharmacokinetics of a single SC dose of tilrekimig with ENHANZE ® in healthy
adults. Tilrekimig is a trispecific monoclonal antibody being developed for the
treatment of atopic dermatitis, asthma, and chronic obstructive pulmonary
disease.

• In September 2026, Halozyme and Incyte expanded their collaboration to
evaluate the SC formulation of axatilimab, a monoclonal antibody targeting
colony-simulating factor-1 receptor, with ENHANZE ® . Under the terms of the new
target agreement, Incyte agreed to make an upfront payment and potential future
milestone payments and royalties on net sales of products developed with ENHANZE
® .

• In August 2026, GSK disclosed plans to initiate a Phase 1b study to evaluate
the pharmacokinetics and safety of a SC belantamab formulation with ENHANZE ®
versus IV belantamab in patients with multiple myeloma while treated with
standard of care.

• The SC formulation of INCA033989, a first-in-class mutant calreticulin-
targeted monoclonal antibody utilizing ENHANZE ® drug delivery technology is
being evaluated in an ongoing Phase 1 study.

• In July 2026, Halozyme and Incyte entered into a global collaboration and
license agreement to evaluate additional SC formulations of INCA033989, a first-
in-class mutant calreticulin-targeted monoclonal antibody, in patients with
mutant calreticulin expressing myeloproliferative neoplasms, utilizing
Halozyme’s proprietary ENHANZE ® drug delivery technology. Under the
collaboration, Incyte also has the option to nominate up to two additional
targets for use with ENHANZE ® . Under the terms of the agreement, Incyte agreed
to make an upfront payment and potential future milestone payments and royalties
on net sales of products developed with ENHANZE ® .

• In July 2026, Janssen announced the FDA granted priority review of the
supplemental Biologics License Application filing for SC amivantamab and
hyaluronidase-lpuj in adults with head and neck squamous cell carcinoma.

• In the third quarter of 2026, the ongoing ARGX-119 adimanebart program was
expanded to include a Phase 1 SC bioavailability study with ENHANZE ® .
Third Quarter 2026 Financial Highlights:
• Total revenue was $493.0 million, compared to $354.3 million in the third
quarter of 2025. The 39% year-over-year increase was primarily driven by royalty
revenue growth and an increase in product sales. Revenue included $341.0 million
in royalties, an increase of 44% compared to $236.0 million in the third quarter
of 2025, primarily driven by continued sales uptake of ENHANZE ® partner
products that have launched since 2020, predominantly by VYVGART ® Hytrulo by
argenx, DARZALEX ® SC by Janssen, and Phesgo by Roche in all geographies and
contributions from other recently launched products.

• Cost of sales was $82.5 million, compared to $55.2 million in the third
quarter of 2025. The increase in cost of sales was primarily due to an increase
in bulk rHuPH20 sales.

• Amortization of intangibles expense was $29.5 million, compared to $17.8
million in the third quarter of 2025. The increase in amortization of
intangibles expense was due to the acquisition of Elektrofi, Inc. (“Elektrofi”)
in November 2025.

• Research and development expense was $27.8 million, compared to $17.3 million
in the third quarter of 2025. The increase was primarily due to the acquisition
of Elektrofi and Surf Bio, Inc. in the fourth quarter of 2025.

• Selling, general and administrative expense was $58.2 million, compared to
$46.1 million in the third quarter of 2025. The increase was primarily due to an
increase in consulting and professional service fees, including litigation costs
incurred in connection with a patent infringement litigation case, the
acquisition of Elektrofi, and an increase in compensation expense.

• Operating income was $295.0 million, compared to $217.9 million in the third
quarter of 2025.

• Net income was $247.0 million, compared to $175.2 million in the third quarter
of 2025.

• EBITDA was $328.7 million, compared to $238.3 million in the third quarter of
2025. Adjusted EBITDA was $336.2 million, compared to $248.2 million in the
third quarter of 2025. 1

• GAAP diluted earnings per share was $2.01, compared to $1.43 in the third
quarter of 2025. Non-GAAP diluted earnings per share was $2.39, compared to
$1.72 in the third quarter of 2025. 1

• Cash, cash equivalents, restricted cash and marketable securities were $1.08
billion on September 30, 2026, compared to $145.4 million on December 31, 2025.
The increase was primarily driven by the issuance of convertible notes and cash
generated from operations.
                                                                                
  Financial Outlook for 2026                                                    
                                                                                
The Company is raising its 2026 financial guidance ranges, which were last
updated on August 6, 2026.
For the full year 2026, the Company expects:
• Total revenue of $1.860 billion to $1.925 billion, representing growth of 33%
to 38% over 2025 total revenue, primarily driven by increases in royalty revenue
and product sales from API.

• Revenue from royalties of $1.235 billion to $1.255 billion, representing
growth of 42% to 45% over 2025.

• Adjusted EBITDA of $1.240 billion to $1.290 billion, representing growth of
89% to 96% over 2025, including new Hypercon™ and Aerocon™ investments of
approximately $60 million.

• Non-GAAP diluted earnings per share of $8.75 to $9.05, representing growth of
111% to 118% over 2025. The Company’s earnings per share guidance includes new
Hypercon™ and Aerocon™ investments of approximately $60 million and does not
consider the impact of potential future share repurchases.
                                                                                
   Table 1. 2026 Financial Guidance                                             
                                                                                
                                                                                
                           Previous Guidance Range     New Guidance Range       
  Total Revenue            $1.835 to $1.910 billion    $1.860 to $1.925         
                                                       billion                  
  Royalty Revenue          $1.220 to $1.245 billion    $1.235 to $1.255         
                                                       billion                  
  Adjusted EBITDA1         $1.225 to $1.280 billion    $1.240 to $1.290         
                                                       billion                  
  Non-GAAP Diluted EPS1    $8.65 to $9.00              $8.75 to $9.05           
                                                                                
1 EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial
measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an
explanation of these measures. Reconciliations between GAAP reported and Non-
GAAP financial information for actual results are provided at the end of this
earnings release.
                                                                                
  Webcast and Conference Call                                                   
                                                                                
Halozyme will host its Quarterly Update Conference Call for the third quarter
ended September 30, 2026 today, Thursday, November 5, 2026, at 1:30 p.m. PT/4:30
p.m. ET. The conference call may be accessed live with pre-registration via
link: https://events.q4inc.com/analyst/811361061?pwd=qhqAVQ9L . The call will
also be webcast live through the “Investors” section of Halozyme’s corporate
website and a recording will be made available following the close of the call.
To access the webcast and additional documents related to the call, please visit
Halozyme.com.
                                                                                
  About Halozyme                                                                
                                                                                
Halozyme is a biopharmaceutical company advancing disruptive solutions to
improve patient experiences and outcomes for emerging and established therapies.
As the innovators of ENHANZE ® drug delivery technology with the proprietary
enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate
the subcutaneous delivery of injected drugs and fluids, with the goal of
reducing treatment burden and improving convenience. ENHANZE ® has touched more
than one million patient lives through ten commercialized products across over
100 global markets and is licensed to leading pharmaceutical and biotechnology
companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-
Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner
products using Hypercon™ and Surf Bio’s hyperconcentration technology, recently
renamed as Aerocon™. Hypercon™ is microparticle technology with the potential to
set a new standard in hyperconcentration of drugs and biologics by reducing
injection volume for the same dosage and enabling administration in at-home and
healthcare-provider settings. The addition of Aerocon™ polymer-based
hyperconcentration technology may further broaden the range of biologics that
can be delivered

subcutaneously. Together, we believe Hypercon™ and Aerocon™ technology
complement ENHANZE ® by enabling creation and delivery of highly concentrated
biologics. The Hypercon™ technology has been licensed to leading
biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex
Pharmaceuticals, and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination
products using advanced auto-injector technologies designed to improve
convenience, reliability and tolerability, enhancing patient comfort and
adherence. The Company has two proprietary commercial products, Hylenex ® and
XYOSTED ® , partnered commercial products and ongoing development programs with
Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris
Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ;
Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations
facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.
                                                                                
  Note Regarding Use of Non-GAAP Financial Measures                             
                                                                                
In addition to disclosing financial measures prepared in accordance with U.S.
generally accepted accounting principles (“GAAP”), this press release and the
accompanying tables contain certain Non-GAAP financial measures. The Company
reports earnings before interest, taxes, depreciation, and amortization
(“EBITDA”), adjusted EBITDA, Non-GAAP diluted earnings per share, Non-GAAP
diluted shares, and guidance with respect to those measures, in addition to, and
not as a substitute for, or superior to, financial measures calculated in
accordance with GAAP. The Company calculates EBITDA excluding interest, taxes,
depreciation and amortization. The Company calculates adjusted EBITDA excluding
one-time items, if any, such as changes in contingent liabilities, inventory
adjustments, impairment charges, transaction costs for business combinations and
share-based compensation acceleration expenses and intellectual property
litigation costs. The Company calculates Non-GAAP diluted earnings per share
excluding share-based compensation expense, amortization of debt discounts,
intangible asset amortization, one-time items, if any, such as changes in
contingent liabilities, inventory adjustments, impairment charges, transaction
costs for business combinations and share-based compensation acceleration
expenses, intellectual property litigation costs, inducement expenses related to
convertible notes, and certain adjustments to income tax expense. The Company
calculates Non-GAAP diluted shares excluding the dilutive impact of convertible
notes which is used in calculating Non-GAAP diluted earnings per share.
Reconciliations between GAAP and Non-GAAP financial measures are included at the
end of this press release. The Company does not provide reconciliations for
forward-looking adjusted measures to GAAP due to the inherent difficulty in
forecasting and quantifying certain amounts that are necessary for such
reconciliation, including adjustments that could be made for changes in share-
based compensation expense and the effects of any discrete income tax items. For
the same reasons, the Company is unable to address the probable significance of
the unavailable information. The Company provides Non-GAAP financial measures
that it believes will be achieved; however, it cannot accurately predict all of
the components of the adjusted calculations and the GAAP measures may be
materially different than the Non-GAAP measures.

The Company evaluates other items of income and expense on an individual basis
for potential inclusion in the calculation of Non-GAAP financial measures and
considers both the quantitative and qualitative aspects of the item, including
(i) its size and nature, (ii) whether or not it relates to the Company’s ongoing
business operations and (iii) whether or not the Company expects it to occur as
part of the Company’s normal business on a regular basis. Non-GAAP financial
measures do not have any standardized meaning and are therefore unlikely to be
comparable to similarly titled measures presented by other companies. These Non-
GAAP financial measures are not meant to be considered in isolation and should
be read in conjunction with the Company’s consolidated financial statements
prepared in accordance with GAAP, and are not prepared under any comprehensive
set of accounting rules or principles. In addition, from time to time in the
future there may be other items that the Company may exclude for purposes of its
Non-GAAP financial measures, and the Company may in

the future cease to exclude items that it has historically excluded for purposes
of its Non-GAAP financial measures.

The Company considers these Non-GAAP financial measures to be important because
they provide useful measures of the operating performance of the Company,
exclusive of factors that do not directly affect what the Company considers to
be its core operating performance, as well as unusual events. The Non-GAAP
measures also allow investors and analysts to make additional comparisons of the
operating activities of the Company’s core business over time and with respect
to other companies, as well as assessing trends and future expectations. The
Company uses Non-GAAP financial information in assessing what it believes is a
meaningful and comparable set of financial performance measures to evaluate
operating trends, as well as in establishing portions of our performance-based
incentive compensation programs.
                                                                                
  Safe Harbor Statement                                                         
                                                                                
In addition to historical information, the statements set forth in this press
release include forward-looking statements including, without limitation,
statements concerning the Company’s financial performance (including the
Company’s expected financial outlook for 2026) and expectations for future
growth, profitability, revenue durability and diversity, total revenue, royalty
revenue, royalty revenue duration, EBITDA, Adjusted EBITDA, and non-GAAP diluted
earnings-per-share, and shareholder value and retirement of outstanding debt.
These forward-looking statements also include statements regarding the
injunction issued by the specialized Dutch patent court of the Hague and other
findings of the court mentioned in this press release, the Company’s potential
receipt of upfront payments and payments associated with achievement of certain
development, regulatory and sales-based milestones, and royalties on sales of
commercialized products from our collaboration agreements. Forward-looking
statements regarding the Company’s ENHANZE® drug delivery technology may include
the possible benefits and attributes of ENHANZE®, its potential application to
aid in the dispersion and absorption of other injected therapeutic drugs and
facilitating more rapid delivery and administration of higher volumes of
injectable medications through subcutaneous delivery including its potential
application with antibody drug conjugates. Forward-looking statements regarding
the Company’s Hypercon™ and Aerocon™ technologies include the possible benefits
and attributes of these technologies, including the potential to reduce
injection volume for the same dosage of drugs and biologics and possibly
enabling administration in at‑home and healthcare‑provider settings and
statements concerning certain other potential benefits of these technologies
including facilitating administration of injectable medications through
subcutaneous delivery by enabling creation and delivery of highly concentrated
biologics and potentially lowering the treatment burden, easing treatment access
and improving the treatment experience for patients. Forward-looking statements
regarding the Company’s business may include potential growth and receipt of
royalty and milestone payments driven by our partners’ development and
commercialization efforts, potential new clinical trial study starts and
advancement of partnered development programs, regulatory submissions and
product launches, the size and growth prospects of our partners’ drug
franchises, potential new or expanded collaborations and collaborative targets,
and potential approvals of new partnered or proprietary products, and the
potential timing of these events. These forward-looking statements are
typically, but not always, identified through use of the words “expect,”
“believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,”
“anticipate,” “plan,” “predict,” “probable,” “potential,” “preliminary,”
“possible,” “should,” “continue,” and other words of similar meaning and involve
risk and uncertainties that could cause actual results to differ materially from
those in the forward-looking statements. Actual results could differ materially
from the expectations contained in these forward-looking statements as a result
of several factors, including uncertainties concerning future matters such as
unexpected changes in market conditions, changes in domestic and foreign
business, changes in the competitive environment in which the Company operates,
judicial decisions related to the injunction and other judicial findings
mentioned in this press release, unexpected early expiration or termination of
the patent terms for the Company’s drug delivery technologies, unexpected levels
of revenues, expenditures and costs, unexpected results or delays in the growth
of the Company’s business, or in the development, regulatory review or
commercialization of the Company’s partnered or proprietary products, regulatory
approval requirements, unexpected adverse events or patient outcomes and
competitive conditions. These and other factors that may result in differences
are discussed in greater detail in the Company’s most recent Annual Report on
Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission, including under the headings “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations”. Except as required by law, the Company undertakes no duty to update
forward-looking statements to reflect events after the date of this release.
Contact:

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

[email protected]
                                                                                
                          Halozyme Therapeutics, Inc.                           
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                  (Unaudited)                                   
                                                                                
                    (In thousands, except per share amounts)                    
                                                                                
           Three                               Nine                             
           Months                              Months                           
           Ended                               Ended                            
           Septem…                             Septe…                           
           30,                                 30,                              
  Reve…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Roya…    $        341,0…    $     236,038    $       889,381    $     609,8…  
  Prod…                                                                         
  sale…             137,3…           94,228            397,378          253,7…  
  net                                                                           
  Reve…                                                                         
  under             14,645           23,998             63,922          81,196  
  coll…                                                                         
  agre…                                                                         
  Total             492,9…          354,264            1,350,…          944,8…  
  reve…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Cost                                                                          
  of                82,475           55,242            240,884          150,0…  
  sales                                                                         
  Amor…                                                                         
  of                29,512           17,762             88,536          53,286  
  inta…                                                                         
  Rese…                                                                         
  and               27,778           17,251             81,002          49,593  
  deve…                                                                         
  Sell…                                                                         
  gene…             58,240           46,088            173,119          130,0…  
  and                                                                           
  admi…                                                                         
  Total                                                                         
  oper…             198,0…          136,343            583,541          382,9…  
  expe…                                                                         
  Oper…             294,9…          217,921            767,140          561,8…  
  inco…                                                                         
  Other                                                                         
  inco…                                                                         
  (exp…                                                                         
  Inve…                                                                         
  and                                                                           
  other              2,172            5,333              6,326          19,042  
  inco…                                                                         
  net                                                                           
  Indu…                                                                         
  expe…                                                                         
  rela…               -465                —               -465               —  
  to                                                                            
  conv…                                                                         
  notes                                                                         
  Inte…             -6,045           -4,296            -17,141          -13,2…  
  expe…                                                                         
  Inco…                                                                         
  befo…                                                                         
  inco…             290,6…          218,958            755,860          567,7…  
  tax                                                                           
  expe…                                                                         
  Inco…                                                                         
  tax               43,582           43,733            128,849          109,2…  
  expe…                                                                         
  Net      $        247,0…    $     175,225    $       627,011    $     458,4…  
  inco…                                                                         
  Earn…                                                                         
  per                                                                           
  share                                                                         
  Basic    $          2.17    $        1.49    $          5.39    $       3.80  
  Dilu…    $          2.01    $        1.43    $          5.12    $       3.68  
  Weig…                                                                         
  aver…                                                                         
  comm…                                                                         
  shar…                                                                         
  outs…                                                                         
  Basic             113,7…          117,219            116,389          120,5…  
  Dilu…             122,6…          122,331            122,349          124,4…  
                                                                                
                                                                                
                          Halozyme Therapeutics, Inc.                           
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (In thousands)                                 
                                                                                
                                              September 30,       December 31,  
                                                       2026               2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Current assets                                                                
  Cash and cash equivalents                $      1,029,988    $       133,820  
  Marketable securities,                             44,399              9,000  
  available-for-sale                                                            
  Accounts receivable, net and contract             525,592            441,273  
  assets                                                                        
  Inventories                                       132,613            176,475  
  Prepaid expenses and other current                114,138             64,639  
  assets                                                                        
  Total current assets                            1,846,730            825,207  
  Property and equipment, net                        82,286             82,137  
  Prepaid expenses and other assets                  68,806             53,551  
  Goodwill                                          581,732            580,360  
  Intangible assets, net                            892,931            981,467  
  Restricted cash                                       861              2,601  
  Total assets                             $      3,473,346    $     2,525,323  
  LIABILITIES AND STOCKHOLDERS’                                                 
  (DEFICIT)                                                                     
  EQUITY                                                                        
  Current liabilities                                                           
  Accounts payable                         $         33,546    $        20,899  
  Accrued expenses                                  136,930            156,193  
  Current portion of long-term debt,                305,612                  —  
  net                                                                           
  Total current liabilities                         476,088            177,092  
  Long-term debt, net                             2,944,691          2,142,630  
  Other long-term liabilities                       101,466            113,863  
  Deferred tax liabilities, net                       6,340             42,924  
  Total liabilities                               3,528,585          2,476,509  
  Stockholders’ (deficit) equity                                                
  Common stock                                          114                118  
  Additional paid-in capital                              —             12,002  
  Accumulated other comprehensive loss                2,781            -18,092  
  (Accumulated Deficit) Retained                    -58,134             54,786  
  earnings                                                                      
  Total stockholders’ (deficit) equity              -55,239             48,814  
  Total liabilities and stockholders’      $      3,473,346    $     2,525,323  
  (deficit) equity                                                              
                                                                                
                                                                                
                          Halozyme Therapeutics, Inc.                           
                                                                                
                                                                                
                        GAAP to Non-GAAP Reconciliations                        
                                                                                
                                                                                
                                     EBITDA                                     
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (In thousands)                                 
                                                                                
                                     Three Months Ended                         
                                     September 30,          2026          2025  
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP Net Income                    $                   247,049    $  175,225  
  Adjustments                                                                   
  Investment and other income,                            -2,172        -5,334  
  net                                                                           
  Interest expense                                         6,045         4,296  
  Income tax expense                                      43,582        43,733  
  Depreciation and amortization                           34,199        20,420  
  EBITDA                                                 328,703       238,340  
  Adjustments                                                                   
  Transaction costs for business                               —         3,871  
  combinations(1)                                                               
  Intellectual property                                                         
  litigation                                               7,452         6,038  
  costs(2)                                                                      
  Adjusted EBITDA                    $                   336,155    $  248,249  
                                                                                
(1) Amount represents incremental costs including legal and advisory fees
incurred in association with the acquisition of Elektrofi.

(2) Adjustment relates to litigation costs incurred by Halozyme in connection
with Halozyme’s patent infringement litigation against Merck Sharp & Dohme LLC
(“Merck”). These charges are excluded because the Company does not believe they
are reflective of the Company’s ongoing business and operating results.
                                                                                
                          Halozyme Therapeutics, Inc.                           
                                                                                
                                                                                
                        GAAP to Non-GAAP Reconciliations                        
                                                                                
                                                                                
                           Net Income and Diluted EPS                           
                                                                                
                                  (Unaudited)                                   
                                                                                
                    (In thousands, except per share amounts)                    
                                                                                
                     Three Months                                               
                     Ended                                                      
                     September 30,        2026                   2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP Net Income    $                 247,049             $  175,225           
  Adjustments                                                                   
  Inducement                                                                    
  expense related                                                               
  to                                       465                      —           
  convertible                                                                   
  notes                                                                         
  Share-based                           16,802                 12,160           
  compensation                                                                  
  Amortization of                        2,220                  1,858           
  debt discount                                                                 
  Amortization of                                                               
  intangible                            29,512                 17,762           
  assets                                                                        
  Transaction                                                                   
  costs for                                  —                  3,871           
  business                                                                      
  combinations(1)                                                               
  Intellectual                                                                  
  property                               7,452                  6,038           
  litigation                                                                    
  costs(2)                                                                      
  Income tax                                                                    
  effect of above                      -19,699                -10,120           
  adjustments(3)                                                                
  Non-GAAP Net       $                 283,801             $  206,794           
  Income                                                                        
  GAAP Diluted       $                    2.01             $     1.43           
  EPS                                                                           
  Adjustments                                                                   
  Inducement                                                                    
  expense related                                                               
  to                                      0.01                      —           
  convertible                                                                   
  notes                                                                         
  Share-based                             0.15                   0.10           
  compensation                                                                  
  Amortization of                         0.02                   0.02           
  debt discount                                                                 
  Amortization of                                                               
  intangible                              0.25                   0.15           
  assets                                                                        
  Transaction                                                                   
  costs for                                  —                   0.03           
  business                                                                      
  combinations(1)                                                               
  Intellectual                                                                  
  property                                0.07                   0.05           
  litigation                                                                    
  costs(2)                                                                      
  Income tax                                                                    
  effect of above                        -0.17                  -0.08           
  adjustments(3)                                                                
  Non-GAAP           $                    2.39             $     1.72           
  Diluted EPS                                                                   
  GAAP Diluted                                  122,611                122,331  
  Shares                                                                        
  Adjustments                                                                   
  Adjustment for                                                                
  dilutive impact                                                               
  of                                             -3,728                 -2,014  
  convertible                                                                   
  notes(4)                                                                      
  Non-GAAP                                      118,883                120,317  
  Diluted Shares                                                                
                                                                                
Dollar amounts, as presented, are rounded. Consequently, totals may not add up. 
.

(1) Amount represents incremental costs including legal and advisory fees
incurred in association with the acquisition of Elektrofi.

(2) Adjustment relates to litigation costs incurred by Halozyme in connection
with Halozyme’s patent infringement litigation against Merck. These charges are
excluded because the Company does not believe they are reflective of the
Company’s ongoing business and operating results.

(3) Adjustments relate to taxes for the reconciling items, as well as excess
benefits or tax deficiencies from share-based compensation, and the quarterly
impact of other discrete items.

(4) Adjustment made for the dilutive effect of our convertible notes due 2028,
2031 and 2032 when the effect is not the same on a GAAP and Non-GAAP basis for
the reporting period.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.